[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"c-met\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:c-met":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,76,102,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100604874","phase-2-a-study-to-assess-adverse-events-and-change-in-disease-activity-of-intravenous-iv-telisotuzumab-adizutecan-monotherapy-or-in-combination-with-osimertinib-compared-to-standard-of-care-in-adult-participants-with-locally-advanced-or-metastatic-egfr-mutated-non-squamous-non-small-cell-lung-cancer-100604874",false,"NCT07155187","A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","A Phase 2\u002F3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.\n* Provide recently obtained tumor tissue during Screening for c-Met immunohistochemistry (IHC) testing (and study stratification in Phase 2). If recently obtained tumor tissue is not available, archived tumor tissue is also acceptable.\n* Received one prior third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy in the adjuvant, locally advanced, or metastatic setting, either as monotherapy or in combination with other agents, and experienced documented radiographic disease progression on or after therapy for the most recent regimen administered prior to study entry. Participant who has received prior third-generation EGFR TKI therapy in the adjuvant setting must have progressed while on treatment.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n* At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, that has not been previously irradiated.\n\nExclusion Criteria:\n\n* Tumor(s) have adenosquamous or squamous histology or sarcomatoid features.\n* Received more than 1 line of systemic therapy in the locally advanced or metastatic setting.\n* Active\u002Fsymptomatic central nervous system (CNS) metastases. Previously treated brain metastases may be included provided they are radiologically stable.\n* Evidence of active interstitial lung disease (ILD)\u002Fpneumonitis or history of ILD or pneumonitis that required steroids.\n* Have any clinically significant medical conditions or any other reason that the investigator determines would interfere with the participant's participation.","ALL","18 Years",{"count":19,"type":20},490,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to standard of care (SOC).\n\nTelisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. This study will be divided into two stages, in the first stage (phase 2) participants will receive 1 of 2 doses of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib. In the second stage (phase 3) participants will receive the recommended phase 3 dose (RP3D) of telisotuzumab adizutecan, from the previous stage, or SOC. Approximately 490 adult participants with NSCLC will be enrolled in the study in 200 sites around the world.\n\nIn phase 2, participants will receive 1 of 2 intravenous (IV) doses of telisotuzumab adizutecan as a monotherapy or in combination with oral osimertinib. In phase 3, participants will receive the IV RP3D of telisotuzumab adizutecan, or SOC. The study will run for a duration of approximately 69 months.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.",[27,28],"Non-Small Cell Lung Cancer","c-MET",[27,30,31,32,33,34,35],"Telisotuzumab Adizutecan","ABBV-400","Osimertinib","Standard of Care","Cancer","AndroMETa-Lung-713","RECRUITING","2026-10-01",{"date":39,"type":40},"2026-10-05","ACTUAL",{"date":42,"type":40},"2025-12-10",{"date":44,"type":20},"2030-09",{"name":46,"class":47},"AbbVie","INDUSTRY",117,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100593335","phase-2-a-study-to-assess-adverse-events-change-in-disease-activity-of-intravenous-telisotuzumab-adizutecan-in-combination-with-osimertinib-as-first-line-treatment-in-adult-participants-with-locally-advanced-unresectable-or-metastatic-egfr-mutated-non-squamous-non-small-cell-lung-cancer-100593335","NCT07005102","A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","A Phase 2\u002F3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 during the screening period and prior to dosing of study treatment on Cycle 1 Day 1.\n* Must consent to provide recently obtained formalin-fixed, paraffin-embedded (FFPE) tumor tissue (ideally collected during or after locally advanced or metastatic diagnosis) or archived tissue during screening for c-Met immunohistochemistry (IHC) testing and study stratification. c-Met IHC results are required prior to randomization.\n* Must have at least one non-irradiated measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. If only one measurable lesion exists, it is acceptable to be used (as a target lesion) as long as it has not been previously irradiated and as long as it has not been biopsied within 14 days of the baseline tumor assessment scans.\n* Any toxicities from prior systemic anti-cancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Grade 1 or baseline level (except for alopecia \\[any grade\\] or Grade \\\u003C= 2 peripheral neuropathy).\n* Should not have any major, life-threatening conditions and life expectancy as determined by the investigator should be at least 3 months.\n* No prior estimated glomerular filtration rate (EGFR) tyrosine kinase inhibitor (TKI) in the locally advanced and\u002For metastatic setting (except for when it is allowed on study prior to C1D1). Participants treated with prior EGFR TKI in the adjuvant setting are allowed to enroll provided that \\>= 126 months (since last dose of e.g., adjuvant osimertinib) have passed before Cycle 1, Day 1.\n* Diagnosis of histologically or cytologically confirmed metastatic\u002Flocally advanced non-squamous NSCLC with documented classical EGFR mutation (Exon 19 Del or Exon 21 L858R) either alone or in combination with other EGFR mutations as detected by an Food and Drug Administration (FDA)-approved or other validated test in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory (sites in the US) or an accredited Laboratory (sites outside of the US) in accordance with site standard of care. A copy of the test report documenting the EGFR mutation must be available in the participant records.\n\nExclusion Criteria:\n\n* History of interstitial lung disease (ILD), pneumonitis that required treatment with systemic steroids, or any evidence of active ILD\u002Fpneumonitis on screening chest computed tomography (CT) scan.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.\n* Participants has leptomeningeal disease, or participant has spinal cord compression not definitively treated with surgery or radiation.\n* History of any malignancy other than disease under study except for\n\n  1. Malignancy treated with curative intent and with no known active disease present for 2 years before the first dose of study treatment and felt to be at low risk for recurrence by investigator.\n  2. Successfully treated nonmelanoma skin cancer.\n  3. Localized carcinoma in situ of the cervix.\n  4. Breast Cancer; lobular carcinoma in situ or ductal carcinoma in situ that is considered completely cured.",{"count":57,"type":20},854,[23,24],"Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity \"when telisotuzumab adizutecan is given in combination with a fixed dose of osimertinib (Osi)or standard of care (Osi plus platinum\u002Fpemetrexed chemotherapy).\n\nTelisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. Osi is a drug approved for the treatment of NSCLC. This study will be divided into two stages, in the first stage participants will receive increasing doses of telisotuzumab adizutecan with Osi. Participants will then be randomized into 4 groups called treatment arms where 3 groups will receive 1 of 3 doses of telisotuzumab adizutecan from from the dose escalation phase with Osi, or standard of care (Osi plus chemotherapy). In the second stage participants will receive the optimal dose of telisotuzumab adizutecan, from the previous stage, with Osi, or SOC. Approximately 854 adult participants with 1L estimated glomerular filtration rate (EGFR) mut (mutated) not sufficient quantity (NSq) NSCLC will be enrolled in the study in 200 sites worldwide.\n\nIn Stage 1, during dose escalation participants will receive increasing intravenous (IV) doses of telisotuzumab adizutecan with oral Osi tablets. participants will receive 1 of 3 doses of telisotuzumab adizutecan with Osi, or standard of care (Osi plus chemotherapy). In stage 2 participants will receive the optimal dose of IV telisotuzumab adizutecanin with oral Osi tablet, or SOC. The study will run for a duration of approximately 76 months.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.",[61,28],"Non-Squamous Non-Small Cell Lung Cancer",[61,30,32,63,64,65,31,66,34,67,68],"Cisplatin","Carboplatin","Pemetrexed","Stand of Care","Chemotherapy","Platinum Chemotherapy",{"date":39,"type":40},{"date":71,"type":40},"2025-08-03",{"date":73,"type":20},"2036-11",{"name":46,"class":47},65,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100575464","phase-1-study-to-evaluate-adverse-events-and-efficacy-of-intravenous-iv-telisotuzumab-adizutecan-in-combination-with-a-pd-1-immune-checkpoint-inhibitor-in-adult-participants-with-advanced-or-metastatic-non-squamous-nsclc-with-no-prior-treatment-for-advanced-disease-and-no-actionable-genomic-alterations-100575464","NCT06772623","Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","An Open-label Multi-Cohort Phase 1b\u002F2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations","Inclusion Criteria:\n\n* Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study.\n* Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.\n* For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC.\n* For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.\n* Must have documented programmed death ligand 1 (PD-L1) status.\n* For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization.\n* Must have adequate organ function.\n\nExclusion Criteria:\n\n* Known uncontrolled metastases to the central nervous system.\n* History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.",{"count":84,"type":20},252,[86,23],"PHASE1","Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.\n\nTelisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide.\n\nIn the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.",[89,28],"Non Small Cell Lung Carcinoma",[89,91,65,64,63,30,31,92,93,94],"Pembrolizumab","ABBV-181","Budigalimab","AndroMETa-Lung-536",{"date":39,"type":40},{"date":97,"type":40},"2025-03-06",{"date":99,"type":20},"2027-11",{"name":46,"class":47},124,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100559807","phase-2-a-study-to-assess-adverse-events-and-how-intravenously-iv-infused-telisotuzumab-vedotin-abbv-399-moves-through-the-body-as-a-monotherapy-in-adult-participants-with-previously-treated-non-squamous-non-small-cell-lung-cancer-nsclc-100559807","NCT06568939","A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced\u002FMetastatic Non-Squamous Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Projected life expectancy of at least 12 weeks.\n* Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as \\>= 25% tumor cells with 3+ staining (high \\[\\>= 50% 3+\\]; intermediate \\[\\>= 25% - \\\u003C 50%\\]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory\n* Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.\n* Must have a known epidermal growth factor receptor (EGFR) activating mutation status.\n* Actionable alterations in genes other than EGFR are permitted.\n* Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n* Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.\n* Must have progressed on at least 1 line of prior therapy for locally advanced\u002Fmetastatic NSCLC, as stated in the protocol.\n\nExclusion Criteria:\n\n* Adenosquamous or neuroendocrine histology, or sarcomatoid features.\n* EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).\n* Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.\n* Received prior docetaxel therapy.\n* Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.\n* History of other malignancies except those stated in the protocol.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.\n* Unresolved clinically significant adverse event (AE) \\>= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.\n* Major surgery within 21 days prior to randomization.\n* Clinically significant condition(s) including but not limited to those listed in the protocol.\n* Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.\n* Grade \\>= 2 edema or lymphedema.\n* Grade \\>= 2 ascites or pleural effusion.\n* Grade \\>= 2 neuropathy.\n* Active uncontrolled bacterial or viral infection.\n* Active corneal disorder.",{"count":110,"type":20},150,[23],"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.\n\nTelisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.\n\nParticipants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[27,28],[27,115,116,117,118],"NSCLC","Telisotuzumab Vedotin","ABBV-399","TeliMET NSCLC-04",{"date":39,"type":40},{"date":121,"type":40},"2025-01-20",{"date":123,"type":20},"2028-02",{"name":46,"class":47},82,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},"100433801","phase-3-a-study-to-assess-disease-activity-and-adverse-events-of-intravenous-iv-telisotuzumab-vedotin-compared-to-iv-docetaxel-in-adult-participants-with-previously-treated-non-squamous-non-small-cell-lung-cancer-nsclc-100433801","NCT04928846","A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced\u002FMetastatic Non-Squamous Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Projected life expectancy of at least 12 weeks.\n* Participants must have c-Met overexpressing non-small cell lung cancer (NSCLC) as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory using the VENTANA MET (SP44) RxDx assay.\n* Archival or fresh tumor material must be submitted for assessment of c-Met protein expression levels during the Pre-Screening period. Tumor material from the primary tumor site and\u002For metastatic sites are allowed.\n\n  * If a participant was prescreened for Study M14-239 but did not enroll, tumor material previously submitted for Study M14-239 may be used for Study M18-868 Pre-Screening upon confirmation from AbbVie that sufficient evaluable tumor material is available (Except China).\n* A histologically or cytologically documented non-squamous cell NSCLC that is locally advanced or metastatic.\n* A known epidermal growth factor receptor (EGFR) activating mutation status.\n\n  \\-- Participants with EGFR activating mutations are not eligible\n* Actionable alterations in genes other than EGFR are eligible.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n* Have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting.\n* Have progressed on at least 1 line of prior therapy for locally advanced\u002Fmetastatic NSCLC\n\n  * Participants WITHOUT an actionable gene alteration: must have progressed on (or be considered ineligible for) platinum-based chemotherapy and immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy).\n  * Participants WITH an actionable gene alteration for which immune checkpoint inhibitor therapy is not standard of care (e.g., anaplastic lymphoma kinase \\[ALK\\] translocation): must have progressed on (or be considered ineligible for) anti-cancer therapy targeting driver gene alterations and platinum-based chemotherapy.\n\n    * Participants with gene alterations for which immune checkpoint inhibitor is standard of care must have also progressed on (or be considered ineligible for) immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy).\n* Must be considered appropriate for docetaxel therapy based on the assessment of the treating physician.\n* Participants with metastases to the central nervous system (CNS) are eligible only after adequate treatment (such as surgery, radiotherapy, or drug therapy) is provided and:\n\n  * They are asymptomatic and off or on a stable or reducing dose of systemic steroids (on no more than 10 mg per day \\[QD\\] prednisone or equivalent) and\u002For anticonvulsants for at least 2 weeks prior to randomization.\n\nExclusion Criteria:\n\n* Evidence of new, untreated CNS metastases or progressing CNS metastases after treatment.\n* Evidence of leptomeningeal disease.\n* Participants with adenosquamous or neuroendocrine histology, nor sarcomatoid features.\n* Epidermal growth factor receptor (EGFR) activating mutations.\n* Participants who have received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E..\n* Participants who have received prior docetaxel therapy.\n* A history of other malignancies except:\n\n  * Malignancy treated with curative intent and with no known active disease present for \\>=2 years before the first dose of study drug and felt to be at low risk for recurrence by investigator. Additionally, participants must not be receiving any ongoing anti-cancer therapy, including maintenance therapy, prior to randomization..\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated carcinoma in situ without current evidence of disease.\n* A history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, evidence of active pneumonitis on screening chest computed tomography (CT) scan or prior pneumonectomy. A history of prior radiation pneumonitis in the radiation field (fibrosis) is not permitted.\n* Unresolved nor adverse event (AE) \\>= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.\n* Major surgery within 21 days prior to randomization.\n* Clinically significant condition(s) as listed in the protocol.",{"count":134,"type":20},768,[24],"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed.\n\nTelisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin or docetaxel at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 768 adult participants with c-Met overexpressing NSCLC will be enrolled in the study in approximately 330 sites worldwide.\n\nParticipants will receive IV telisotuzumab vedotin every 2 weeks or docetaxel every 3 weeks until meeting study drug discontinuation criteria. At the conclusion of the study, participants who continue to demonstrate clinical benefit may be eligible to receive study treatment via an extension of the study, a rollover study, or through another mechanism.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[138,28],"Non Small Cell Lung Cancer",[140,141,116,117,142,34,138,115,143,144,145],"c-Met Overexpressing Non-Small Cell Lung Cancer","c-Met NSCLC","Docetaxel","TeliMET NSCLC-01","Teliso-V","c-Met protein overexpression",{"date":39,"type":40},{"date":148,"type":40},"2022-03-25",{"date":150,"type":20},"2029-02",{"name":46,"class":47},317]